APA (7th ed.) Citation

Yonemoto, T., Ogasawara, S., Kanogawa, N., Miwa, C., Fujiya, M., Tsuchiya, T., . . . Itobayashi, E. (2025). Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma. Hepatology Research, 55(5), 718. https://doi.org/10.1111/hepr.14160

Chicago Style (17th ed.) Citation

Yonemoto, Takuya, et al. "Evaluating Two Rechallenge Strategies of Immune Checkpoint Inhibitors: Durvalumab Plus Tremelimumab in Advanced Hepatocellular Carcinoma." Hepatology Research 55, no. 5 (2025): 718. https://doi.org/10.1111/hepr.14160.

MLA (9th ed.) Citation

Yonemoto, Takuya, et al. "Evaluating Two Rechallenge Strategies of Immune Checkpoint Inhibitors: Durvalumab Plus Tremelimumab in Advanced Hepatocellular Carcinoma." Hepatology Research, vol. 55, no. 5, 2025, p. 718, https://doi.org/10.1111/hepr.14160.